Credit Suisse will face a public hearing over whether or not the U.S. government should allow the bank to manage Americans' retirement funds after its decision to plead guilty to tax crimes.
A former Societe Generale mortgage-bond trader in New York was sanctioned by the Financial Industry Regulatory Authority for improper transactions.
JPMorgan settled a lawsuit by Texas mineral-rights owners who accused it of cutting sweetheart deals with oil company clients to cheat them out of $681m in compensation.
The global economy is again showing worrying signs of an imminent financial crisis, according to David Cameron, the prime minister of the United Kingdom, who has warned of a dangerous backdrop of instability and uncertainty.
The chairman of scandal-hit outsourcing group Serco is stepping down, saying that he takes “ultimate responsibility” for the string of “operational mis-steps” that have hit the business.
Allergan, the company that makes Botox, is preparing to sell itself to pharmaceutical group Actavis in a $66bn (£42bn) tie-up that will be one of the biggest deals of the year.
Facebook is taking aim at the likes of Google and LinkedIn with a bid to drive business users to the social networking site.
GlaxoSmithKline has once again topped a league table that measures the major pharmaceuticals companies’ efforts in enabling people in developing countries to get the drugs they need, while rivals Pfizer and Sanofi have slipped down the rankings.
The British government has been encouraged to put more effort into supporting “scale-ups” companies, rather than simply focusing on smaller startups.
The European Central Bank is under growing pressure to step up support for the eurozone’s flagging economy after the bloc slipped back into negative inflation in February.
Hedge fund managers may have to face some upheaval in their industry this year.
Credit Suisse’s global head of macro products, David Tait, is leaving the bank as it cuts back businesses tied to interest rates and currencies trading.